MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

Fatima Cardoso,Laura van 't Veer,C Poncet,Josephine Lopes Cardozo,Suzette Delaloge,Jean-Yves Pierga,Peter Vuylsteke,Etienne Brain,Giuseppe Viale,Sherko Kuemmel,Isabel T. Rubio,Gabriele Zoppoli,Alastair M. Thompson,Erika Matos,Khalil Zaman,Florentine Hilbers,Aleksandra Dudek-Peric,Bart Meulemans,Martine Piccart-Gebhart,Emiel J. Th. Rutgers

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

2020

506Background: The 70-gene signature MammaPrint has been shown to identify breast cancer patients for whom adjuvant chemotherapy (CT) could be safely omitted even in the presence of unfavorable sta...

Keywords:

adjuvant chemotherapy
prospective trial
Internal medicine
MammaPrint
Oncology
Gene signature
long term results
Breast cancer
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations